which show promise for combination therapy in AD. "Growing research suggests metabolic pathways (such as cellular metabolism) ...

Longer-term, Eisai and Biogen are hoping for further evidence to support Leqembi from the phase 3 AHEAD 3-45 trial, which ...

AbbVie (ABBV) announced Monday that it is buying Aliada Therapeutics for $1.4 billion. The deal includes Aliada’s lead drug ...

Key Laboratory of Molecular Biophysics, Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin 300401, P. R. China ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

Interim data from a phase I/II study showed that LX1001, an investigational gene therapy for APOE4-associated ... to treat ...

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

The United Kingdom medicines authority approved the Alzheimer’s disease drug Kisunla (donanemab) last week for certain patients. This follows the Unites States Food and Drug Administration ...

Pharmaceutical giant AbbVie announced a deal to acquire biotech company Aliada Therapeutics, which is developing a potential ...

AbbVie will buy Aliada Therapeutics for US$1.4 billion in cash, it said on Monday (Oct 28), gaining access to the privately ...